PMV Pharmaceuticals, Inc. (PMVP)

In the past six months, PMV Pharmaceuticals' stock has experienced volatility, with its price ranging from a 52-week low of $0.81 to a high of $1.88. The stock price as of March 25, 2026, was $1.37 per share. Key events impacting the stock price include the Third Quarter 2025 Financial Results reported on November 12, 2025, with a net loss of $0.400 USD per share. Updated Rezatapopt Monotherapy Interim Data was announced on November 12, 2025, from the ongoing PYNNACLE Phase 2 trial. On October 24, 2025, PMV Pharmaceuticals announced updated Phase 2 pivotal data for Rezatapopt, showing a 34% overall response rate (ORR) among 103 evaluable patients, with a median duration of response of 7.6 months. The ovarian cancer cohort showed a 46% ORR. On February 26, 2026, the New England Journal of Medicine published first-in-human rezatapopt data. Full Year 2025 Financial Results were reported on March 6, 2026, with a GAAP EPS of -$1.48, beating estimates, and a cash runway to the end of Q2 2027. The company participated in the TD Cowen 46th Annual Health Care Conference on March 2, 2026. As of March 22, 2026, the stock price was down 13.53% for the month of March, and short interest in PMV Pharmaceuticals recently increased by 20.47%.

As a clinical-stage biopharmaceutical company focused on drug discovery and development, PMV Pharmaceuticals, Inc. does not generate commercial revenue from product sales. Therefore, traditional concepts of demand seasonality for products and services are not applicable to its current business model. The company's operations are centered on internal research and development, clinical trials, regulatory activities, and intellectual property management. Its financial performance is primarily characterized by cash burn to fund these activities, rather than revenue generation influenced by seasonal demand.

PMV Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology therapies, particularly those that restore the tumor-suppressor function of mutated p53 proteins. Their lead product candidate is rezatapopt (PC14586), an orally available small molecule in Phase 2 clinical trials designed to correct the misfolding of the mutant p53 protein. The company does not currently generate commercial revenue.

PMV Pharmaceuticals is headquartered in Princeton, New Jersey, which serves as its main center for corporate management and research operations. The company's activities are predominantly based in North America, with clinical trial sites distributed across the United States. Its international footprint is reflected through global clinical trials and regulatory interactions in various regions, conducted through third-party contract research organizations and academic collaborators.

PMV Pharmaceuticals positions itself as a precision oncology company pioneering therapies that target p53 mutations. The company's reputation is largely tied to its scientific advancements and clinical trial progress for its lead candidate, rezatapopt. Positive clinical trial data, including a 34% overall response rate in advanced solid tumors and a 46% ORR in ovarian cancer, contributes positively to its scientific and clinical reputation. The publication of first-in-human rezatapopt data in the New England Journal of Medicine enhances the company's scientific credibility. The partnership with Foundation Medicine, Inc. suggests a commitment to precise patient identification and treatment. Its stock performance has been poor, leading to significant shareholder dilution and a substantial decline in market capitalization since its IPO, which can impact investor confidence.

PMV Pharmaceuticals, Inc. has a significant institutional ownership, with 90.20% of its stock held by institutions. As of March 31, 2026, there were 68 institutional owners holding a total of 37,466,853 shares. Major institutional shareholders include BML Capital Management, LLC, Orbimed Advisors Llc, Tang Capital Management Llc, ArrowMark Colorado Holdings LLC, Sio Capital Management, LLC, Euclidean Capital LLC, Vanguard Group Inc, Acadian Asset Management Llc, Stonepine Capital Management, LLC, and BlackRock, Inc. Individual insiders hold 3.37% of the stock, including Orbimed Advisors Llc, David Henry Mack (CEO), Robert Ticktin, Deepika Jalota (Chief Development Officer), and Michael Carulli (Chief Financial Officer). There have been insider sales reported in the past year by OrbiMed Advisors LLC, Michael Carulli, Deepika Jalota, David Mack, and Robert Ticktin.